Semaglutide
Anonymous community reports on semaglutide — weight loss outcomes, side effects, dose titration, and comparisons with tirzepatide. Real accounts from GLP-1 users.
6 anonymous reports
related topics:
Community Q&A
- What do community accounts say semaglutide actually does?
- Community accounts frame semaglutide almost entirely as a weight loss intervention — its off-label peptide use mirrors exactly what clinical trials show. The most consistently described mechanism in accounts: appetite suppression so effective that users describe forgetting to eat. Dose titration patterns dominate accounts — nearly all describe starting at 0.25mg weekly and stepping up monthly. The community framing is consistent: semaglutide is not a peptide in the traditional biohacker sense but a pharmaceutical GLP-1 agonist that happens to be injectable, and the community uses it accordingly.
- How much weight loss do people report with semaglutide?
- Community accounts cluster between 15–40 lbs over 3–6 months at maintenance doses, with considerable variation by starting weight and dose reached. Accounts from users who titrated to 1mg or 2mg weekly report the higher end of this range. The accounts describing the most dramatic results are typically from heavier starting weights. A consistent pattern in community reports: loss plateaus around 4–6 months and requires either dose increase or cycling off. Accounts comparing semaglutide to tirzepatide consistently give tirzepatide the edge on total weight loss — a finding that shapes where more experienced users end up.
- What side effects does semaglutide cause according to community reports?
- Nausea is the dominant side effect in community accounts — described as worst during titration, fading over weeks, and reliably returning with each dose increase. Constipation appears almost as frequently as nausea in accounts; some describe it as the more persistent problem. 'Ozempic face' (facial volume loss from rapid weight loss) appears in longer-term accounts, often described as the most aesthetically unwanted consequence. Hair shedding appears in a subset of accounts and is attributed to telogen effluvium from rapid weight loss rather than to semaglutide directly. The side effect profile is almost entirely dose-dependent in community reports.
- How does semaglutide compare to tirzepatide in community accounts?
- The community verdict is consistent: tirzepatide produces more weight loss at equivalent injection frequency, but semaglutide is more accessible and often better tolerated. Accounts that have used both describe tirzepatide as the upgrade for people who plateau on semaglutide or want maximum fat loss. Semaglutide appears more frequently in accounts from users on prescribed doses rather than self-sourced protocols. The framing in most comparative accounts: semaglutide is the starting point, tirzepatide is the escalation. Cost and sourcing ease are the most commonly cited reasons for staying on semaglutide despite preferring tirzepatide's outcomes.
- Does semaglutide cause constipation — what does the community actually report?
- Constipation is the second most-reported GI side effect of semaglutide in this archive, behind nausea. Unlike nausea, which most accounts describe as fading after the first few weeks on each dose, constipation is described as more persistent and less responsive to dose stabilization. Community management approaches described in accounts: significantly increased water intake, magnesium supplementation, and fibre adjustment. Some accounts describe alternating constipation and loose stools — GI motility disruption rather than one-directional. The pattern across accounts: GI symptoms are most severe during dose escalation, improve somewhat at stable doses, and return with each increase. Accounts from users who titrated slowly (one-dose-per-month protocols) describe consistently milder GI effects than those who escalated faster.